Early pioneer in recombinant protein-based therapeutics
Zymogenetics was a biopharmaceutical company focusing on discovery, development, and commercialization of protein-based therapeutics to treat cardiovascular, autoimmune, and viral diseases. Zymogenetics completed its IPO on NASDAQ in 2002 and was acquired by BMS in 2010.
